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A b s t r a c t  
Worldwide prevalence of type 2 diabetes is increasing with alarming proportions. Metformin is 
the first-line oral antidiabetic drug of choice for the treatment of type 2 diabetes. The objectives of 
the present study were to develop Metformin solid lipid nanoparticles  (M-SLN) and incorporate it in 
the transdermal patches. M-SLN was evaluated for Particle size, Zeta potential, Surface morphology 
by scanning electron microscopy (SEM), Transmission electron microscopy (TEM) and In vitro- In 
vivo release studies. Patches were evaluated by Ex-vivo skin permeation studies. M-SLN was 
prepared by solvent diffusion technique using propylene glycol (solvent), polymethacrylic acid 
(polymer) and Soya lecithin (lipid base).  After doing the evaluation of the above mentioned 
pharmaceutical parameters, M-SLN was loaded in Methocel K100M transdermal patches. Ex-vivo 
skin permeation studies were conducted on male Wistar ratÊs skin using Franz-type diffusion Cells. 
The particle size of M-SLN varied among the formulation due to variation in the composition of 
formulations. Zeta potential of best formulation was found to be +27mV. SEM  and  TEM indicates 
discrete spherical structure without aggregation. Drug content was found to be 1.45mg/patch. The 
ex-vivo permeation studies indicate that the high cumulative amount of drug is permeated from M-
SLNs. Our study proves the successful delivery of M-SLN from transdermal patch, and 
Histopathological studies confirmed that the M-SLN transdermal patch only provoked an acceptable 
modest inflammatory response. These results support the feasibility of developing transdermal 
metformin for human applications. Thus, transdermal delivery of M-SLN is a safe, painless and cost 
effective drug delivery system for diabetes patients. 
Keywords: Solid lipid nanoparticles, Metformin, Transdermal patches, In vitro-In vivo studies, Ex-
vivo studies, histopathological studies. 
 
Introduction 
Non-insulin-dependent diabetes mellitus (NIDDM or type 2 
diabetes) constitutes a major risk factor for cardiovascular mortality 
and morbidity that is aggravated in turn by obesity, hyperlipidaemia 
and hypertension [1-4]. The prevalence of type 2 diabetes has 
reached epidemic proportions and is continuously increasing 
worldwide. As per global estimates predict that the number of 
cases were about 220 million in the year 2011, which represents a 
50% increase in the prevalence compared to the year 2001, and 
prediction is that there will be about  370 million cases in the year 
2030 [5,6]. India is going to be the Diabetes capital of world. This 
makes understanding of the pathogenesis of type 2 diabetes 
crucial in order to implement rational treatment strategies. Type 2 
diabetes results from an insufficient compensatory insulin secretion 
to insulin resistance. Mostly insulin resistance is an early event due 
to environmental factors, obesity, and β-cell function decline a 
gradual but generally late event [7,8]. Main goals of management 
in patients with diabetes are to lower the incidence of degenerative  
 
 
complications and the risk of fatal or non-fatal health events, to 
improve quality of life, and to increase life expectancy [9]. 
Metformin hydrochloride lowers both basal and postprandial-
elevated blood glucose in patients with type 2 diabetes [10,11]. 
Some high incidence of concomitant gastrointestinal symptoms, 
such as abdominal discomfort, nausea, and diarrhoea, may occur 
during the treatment [12-14]. Recent advances in nanoparticulate 
systems for improved drug delivery display a great potential for the 
administration of wide variety of active pharmaceuticals [15]. Many 
approaches have been used to enhance the penetration of drugs 
through skin. The role of these systems in the long-term treatment 
of diabetes, however, remains debatable [16]. Especially 
questionable are those methods involving physical or chemical 
disruption of the skin, which might cause chronic pathological 
changes. Transdermal route of drug administration have unique 
advantages drug bypass the first pass metabolism and reaches in 
the systemic circulation. Painless, noninvasive, and patient-friendly 
ISSN: 0975-0215 
  
This work is licensed under a Creative Commons Attribution 3.0 License.  
Sharma et al. International Journal of Drug Delivery 5 (2) 137-145 [2013] 
 
PAGE | 138 |
 
 
application of patches offers good patient compliance and patches 
are also easy to remove in the event of hyperinsulinemia [17]. 
As an alternative carrier, the distinct feature of Solid lipid 
Nanoparticle (SLN) is that it integrates the benefits of traditional 
nanoemulsions and polymeric nanoparticles. SLN is by nature a 
special form of nanoemulsions wherein the matrix material is solid 
lipid (e.g. highly purified triglycerides, complex glyceride mixture, 
wax, etc.) instead of liquid lipid, i.e. oil. In comparison with 
nanoemulsions, SLN possesses good stability and is able to 
control the release of the incorporated drug. When compared with 
polymeric nanoparticles, the physiological lipids-made SLN is 
definitely better tolerated by the human body and its lipophilic 
nature helps it to penetrate the Skin [18-19].   The current study 
was undertaken to formulate Metformin solid lipid nanoparticles (M-
SLN) employing solvent diffusion technique [18-19]. Animal studies 
were carried out of the Metformin solid lipid nanoparticles 
incorporated in Transdermal patches. In vitro release of drugs and 
histopathological evaluation of inflammation were investigated. 
Materials and Methods  
Materials 
Polymethacrylic acid, Propylene glycol and Soya lecithin was 
purchased from Sigma Aldrich (CA,USA). Metformin was a kind gift 
from Ranbaxy Research Labs (New Delhi, India). Methocel 
(K100M), Acetone (HPLC grade) and Ethanol (HPLC grade) were 
purchased from Merck (Mumbai, India). Streptozocin was obtained 
from BioVision (PA, USA). Jolen hair removing cream (Jolen Inc. 
CA, USA) was used as chemical depilatory. Water used in all 
experiments was obtained from a Milli-Q Synergy 185 water 
purification system (Cedex, France). All other materials and 
reagents were of analytical or pharmaceutical grade, and used as 
received. 
Experimental models  
Male Wistar rats weighing 240μ20 g (12-16 weeks) and Balb C 
mice 20-30 g (8 weeks) were obtained from the Experimental 
Animal Center of JSS College of Pharmacy, Mysore. All animals 
were fed with a standard laboratory diet and water. They were 
housed in a specific room at a temperature of 20ă25 ĈC and 
50 μ 5% relative humidity under a 12-h dark/light cycle and 
acclimatized for l week before the start of experiment. All 
experimental procedures involving animals were approved by the 
Animal Ethical Committee of JSS University. 
Preparation of Metformin - solid lipid Nanoparticles (M-
SLN) 
Nanoparticles containing Metformin were prepared using solvent 
diffusion technique [20-21]. Drug was dissolved in water, and then 
acetone (co-solvent) was added into this solution. Co-solvent was 
needed in order to make the inner phase more homogeneous. 
Then polymethacrylic acid (Polymer) and 150 mg of propylene 
glycol were dissolved in chloroform along with 3 mg soya lecithin 
(lipid base) and this solution was added to the drug solution to form 
dispersion. The dispersion was added to 10 ml of aqueous ethanol 
solution (70%). After 5 minutes of mixing, the organic solvents 
were removed by evaporation at 35Ĉ under normal pressure, 
nanoparticles were separated by using cooling centrifuge (10000 
rpm for 20 min), supernatant were removed and nanoparticles 
washed with water and dried at room temperature in a desicator. 
By following the above mentioned procedure five other batches of 
nanoparticles ratio of 1:1, 1:2, 1:3, 1:4 and 1:5 were prepared and 
named F1, F2, F3, F4 and F5 respectively. 
 
Preparation of Metformin transdermal patches 
For preparation of transdermal patches Methocel K100M were 
used as a film forming agent [22-23]. The polymer was soaked 
overnight in water and then 50mg of prepared M-SLN were 
incorporated and mixed uniformly. Suspension was casted on a 
glass mould and after drying the patches were cut into small pieces 
and stored in between the sheet of wax paper in desiccator for 
further studies. 
 
Particle size, zeta potential and surface morphology  
Particle size and Zeta potential was determined using Photon 
correlation spectroscopy. Surface morphology (roundness, 
smoothness, and formation of aggregates) were studied by 
Scanning electron microscopy (SEM) and Transmission Electron 
Microscopy (TEM). 
Photon correlation spectroscopy 
Particle size was determined by photon correlation spectroscopy 
(PCS) which yields the mean particle size (Z-average), and the 
polydispersity index (PI), which measures the width of the size 
distribution. PCS was performed with Zetasizer Nano S (Malvern 
Instruments, Malvern, UK) at a detection angle of 173Ĉ, at 25ĈC. 
Samples were suitably diluted in ultrapurified water. Each value 
was measured in triplicate. The results are shown as          mean μ 
standard deviation. 
Scanning electronic microscopy (SEM)  
The SEM analysis was performed in order to investigate the 
morphological characteristics of the SLNÊS. Prior to analysis, the 
sample was diluted with ultrapurified water, placed on a double 
side carbon tape mounted onto an aluminium stud, and dried in a 
desiccator. Sample was then sputter coated with gold in order to 
make it conducting. SEM images were recorded on a Jeol, JSM 
5310, (Tokyo, Japan) scanning electron microscope, with an 
acceleration voltage of 25 kV. 
Transmission Electron Microscopy (TEM)  
Transmission electron microscopy (TEM) was employed to 
evaluate the shape of the nanoparticles containing Metformin. A 
Philips CM 10 transmission electron microscope was used, and 
particle size was measured using NIH image software. 
Nanoparticle suspensions, at a concentration of 0.5% (w/v) of 
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nanoparticle, were sprayed on Formwar-coated copper grids and 
air-dried before observation. 
Drug content 
Drug content was determined by ultrafiltration-centrifugation 
method [24-25]. The ultrafiltration-centrifugation method was 
carried out through centrifugal filters (Amicon® Ultra-4, Millipore, 
Germany) with a 100 kDa molecular weight cut-off. Briefly, 1mL of 
M-SLN plus 1mL of methanol were placed into the upper chamber 
of the centrifuge (Kubota 1720 centrifuge), which was centrifuged 
at 4000ïg for 90 min at 4C. Methanol was added in order to 
dissolve crystals possibly present in the external phase of the M-
SLN dispersion. The amount of free drug in the aqueous dispersion 
phase, collected in the outer chamber of the centrifugal filter after 
separation, was determined by UV-Vis spectrophotometry at 233 
nm after suitable dilution. 
Fourier Transform Infra-red Spectroscopy (FT-IR) 
analysis 
In order to obtain information about the drug polymer interaction 
and stability of drug, the FT-IR spectra of pure Metformin and 
Polymethacrylic acid nanoparticles loaded with Metformin were 
recorded. Samples were prepared using potassium bromide pellet 
method. Then placed in the FT-IR device (Spectrum 400, 
PerkinElmer) and measured using four scans for each spectrum, 
with a resolution of 1cmî1 and a scan speed of 0.5. Spectra were 
collected between 4000 and 400cmî1. 
In-Vitro Studies 
Drug content analysis 
The patches (n=3) of specified area 3cm2 were weighted and 
dissolved in 100ml methanol. The solution was filtered through 
membrane filter and drug content were analyzed by HPLC. 
Preparation of skin for skin permeation studies 
The Male Wistar rats were sacrificed and the hair in abdominal 
region was removed with depilatory, and examined for integrity 
using a lamp inspecting Method [26-29]. The subcutaneous fat and 
connective tissue were carefully removed by scalpel. Finally skin 
was rinsed with physiological saline and stored at -20ĈC in an 
aluminium foil. 
Ex-vivo permeation study 
The skin samples were mounted carefully on Franz-type diffusion 
Cells with the stratum corneum side up with an effective diffusion 
area of 1.72 cmñ [28-29]. The receiver compartments were filled 
with 10 ml of physiological saline to ensure sink condition. The 
diffusion cells were maintained at (37μ0.5)ĈC with stirring at 100 
rpm throughout the experiment. 3 cm transdermal patch of 
Metformin was mounted onto skin surface 1 ml of the sample was 
collected from the medium at predetermined time Interval of (0, 1.7, 
2.5, 4.5, 8.2, 10.7, 12.8, 24 hrs.) and replace same volume of fresh 
physiological saline. All the samples were filtered through a 
membrane filter and analysed by HPLC. 
In-Vivo Studies 
Preparation of animal for studies 
Male Wistar rats were housed, with standard diet and water for 
three days, and then they were fasted overnight before experiment. 
Hair on the backside of the rats was removed with a depilatory 
cream. Prior to the day of the experiment, animals were divided 
into 3 groups (n=6) of normal and diabetes rats. The rats were 
treated as following 
Group I- Placebo patch (control) prepared by Methocel without 
nanoparticles  
Group II - Metformin oral administration contain 2mg drug  
Group III-Transdermal patch (3 cm2) contains Metformin 
nanoparticles 
Induction of diabetes  
Diabetes was induced by injecting 60 mg/kg of Streptozocin (STZ) 
dissolved in 0.1M   citrateăcitrate sodium buffer (pH 4.5) intra 
peritoneally in all the 3 groups [30-31]. After allowing the diabetic 
rats for stabilization over 72 hours. The blood glucose level was 
estimated by using Metformin transdermal patches. Blood samples 
were collected from the tail vein before and after treatment to 
determine blood glucose levels. These samples were taken at 
scheduled times of 0,2,4,8,10,12,24,36 & 48 hrs. Blood glucose 
levels were obtained by Using the once touch glucometer (Roche, 
Germany). 
Statistical analysis 
Results are expressed as mean μ SEM values. Statistical 
significances were evaluated using student t test. A value of 
p<0.05 was considered significant. 
 
In vivo  evaluation of M-SLN Transdermal patches for 
biocompatibility 
Balb C mice were used to examine the biocompatibility of M-SLN 
Transdermal patches. After being sterilized by 60Co-γ radiation, M-
SLN Transdermal patches was subcutaneously applied on the 
back of the mice, respectively. The control group was applied with 
same Transdermal patch without M-SLN to make a comparison 
keeping similar environment. Individual mouse weight was taken 
daily prior to their scheduled sacrifice on days 1, 7, 14 and 21.The 
skin was cut and the applied site was exposed. Immediately after 
necropsy, skin tissues from the applied sites were retrieved and 
fixed in BouinÊs solution for 7 days, and then washed by flowing 
water for 24 h. After being bisected into pieces with a thickness of 
2 mm, all tissues were initially dehydrated in a graded series of 
alcohol and then embedded in paraffin. The transverse sections 
(4ă5 øm thick) were prepared using rotator microtome and stained 
with hematoxylin and eosin dye for histopathological examination. 
The histological changes, such as acuteăchronic inflammatory 
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symptoms, fibroblastic proliferation, foreign material deposits, and 
any other inflammation symptoms were evaluated through 
observation under a light microscope.  
Results  
Metformin nanoparticles with varying proportions of Metformin and 
polymethacrylic acid were prepared by solvent diffusion technique. 
The scanning electron microphotograph of Metformin 
nanoparticles, Shown in Figure.2 (a&b) and Transmission electron 
micrograph in Figure.3. It indicate that Metformin nanoparticles 
have a discrete spherical structure without aggregation. The 
particle size of nanoparticles varied some what among the 
formulation due to variation in the composition of formulations as 
shown in Table.1. 
Zeta potential of best formulation was determined and it was found 
+27mV. Since there was a decrease of surface potential, it could 
be concluded that a part of drug was absorbed on the polymeric 
particles. The drug content was determined by centrifugation 
 
 
 
Table1-Five batches of nanoparticles ratio of 1:1, 1:2, 1:3, 1:4 and 
1:5 were prepared and  named F1, F2, F3, F4 and F5 respectively 
Formulation    
code 
Drug : Polymer   
ratio 
Drug Content*
(%) 
Particle Size 
*(nm) 
F1 1:1 68.32μ0.02 12μ8
F2 1:2 74.3μ0.08 225μ5
F3 1:3 80.83μ0.03 237μ9
F4 1:4 94.62μ0.02 242μ5
F5 1:5 78.96μ0.04 203μ4
* Average of three preparation μ S.D  
method and it was maximum in formulation F4. The nanoparticles 
exhibited an increase in drug content with an increased in the 
polymer ratio, up to particular concentration (1:4). A decrease in 
drug content was observed after that point due to the saturation 
capacity of polymer. In FT-IR study the characteristic peak due to 
pure Metformin has appeared in the spectra of nanoparticles 
without any markable change in the position (Figure.1). It indicated 
that there was no chemical interaction between Metformin and 
polymethacrylic acid. 
 
Figure: 1-FTIR spectra of (a) Metformin, (b) F1, (c) F2, (d) F3, (e) F4, (f) F5 
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Scanning Electron Microscopy (SEM)  
SEM picture are shown in Figure. 2. (a&b). Non-aggregated 
microcapsules with almost spherical shape were obtained for all 
the formulations. Nanospheres did not have a smooth surface 
indicating that Metformin was drug present on the surface. 
 
 
Figure: 2- Scanning electron microphotograph of Metformin nanoparticles  
                      (a) At magnification 250 x                           (b) At magnification 40 x 
 
Transmission Electron Microscopy (TEM)  
To investigate Nanoparticle size and morphology further, 
microscopy studies were carried out using TEM analysis. TEM 
photomicrograph of the loaded nanoparticles are reported in 
Figure. 3 and confirm their previously ascertained sizes. Metformin 
loaded nanoparticles were spherical in shape with a rather uniform 
distribution. 
 
Figure:3- Transmission electron micrographs (TEM) of Metformin 
nanoparticles (46000X) 
Loading evaluation of Solid lipid nanoparticles on 
transdermal patches 
The solid lipid nanoparticles containing Metformin loaded in 
Methocel K100M transdermal patches. This polymer is highly 
hydrophilic, so the lipophillic M-SLN are not soluble and structure 
of M-SLN remains intact. The drug content of each patch was 
found to be uniform and ranged between 92.21 μ 0.12 to 96.00 μ 
0.15 % (1.45mg/patch). 
Ex-vivo skin permeation studies  
Result of ex-vivo and in-vivo skin permeation of M-SLN from 
transdermal patches is shown in Figure 4. The cumulative amount 
of drug release from nanoparticle made by polymethacrylic acid 
and Soya lecithin 291 μ 2.16 μg/cm respectively .The release was 
shown in Figure 4. 
 
Figure:4- Ex-vivo diffusion studies showing the time course of 
cumulative drug diffusion 
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Hypoglycemic effects 
The reports showed decreased blood glucose level by using 
transdermal patches loaded with M-SLN when compared with oral  
administration of Metformin (2mg) in both normal and diabetes rats. 
The time course profile of blood glucose response in rats were 
shown in Table 2. 
The blood glucose level in normal rats drastically reduced in orally 
administered drug upon 10 hrs and was reported as 53.08 μ 
0.18mg/ dl and 34.40 μ0.04 mg/dl for 48 hrs in the case of 
transdermal patches containing nanoparticles. In STZ induced 
diabetes rats, the blood glucose level gradually reduced up to 
97.48 mg/dl at t=10 hrs from 330.67 mg/dl. Transdermal patches 
containing M-SLN produced maximum drop of blood glucose at 
91.74 mg/dl at 48 hrs. Neither placebo patch applied showed 
hypoglycemic effect. 
 
 
 
Table:2-Blood glucose level following Control, Oral and M-SLN Loaded patch in normal and diabetic rats 
Normal rats (mg/dl) Diabetes rats (mg/dl) 
Time 
(hrs) 
Placebo Patch 
(Control) 
Oral (2mg) M-SLN loaded 
patch 
Placebo Patch 
(Control) 
Oral    (2mg) M-SLN      loaded 
patch 
0 86.17μ0.12 86.02μ0.34 85.98μ0.24 335.67μ0.02 330.67μ0.10 336.67μ0.10
2 84.33μ0.32 69.60μ0.82 79.16μ0.76 333.33μ0.02 184.42μ0.32 300.18μ0.62
4 84.17μ0.22 67.12μ0.96 76.00μ0.14 335.10μ0.14 128.33μ0.40 260.27μ0.02
8 84.92μ0.53 59.42μ0.16 70.18μ0.38 337.67μ0.12 111.60μ0.62 248.00μ0.22
10 84.04μ0.72 53.08μ0.22 68.66μ0.38 331.45μ0.98 97.48μ0.60 211.92μ0.60
12 84.86μ0.24 71.18μ0.42 64.20μ0.72 339.10μ0.22 227.10μ0.34 195.68μ0.02
24 84.10μ0.41 75.92μ0.44 51.38μ0.34 339.48μ0.62 260.87μ0.10 111.34μ0.06
36 83.98μ0.92 76.64μ0.10 39.42μ0.04 338.62μ0.74 258.44μ0.22 107.62μ0.88
48 84.62μ0.74 77.06μ0.04 34.40μ0.04 339.09μ0.02 268.19μ0.02 91.74μ0.02
Values are expressed as mean μ SEM, n=4, p<0.05. 
 
 
In vivo evaluation of M-SLN Transdermal patches for 
biocompatibility 
M-SLN Transdermal patches were subcutaneously applied on the 
back of the mice, respectively. The control group was applied with 
same Transdermal patch without M-SLN to make a comparison 
keeping similar environment. All the mice were healthy throughout 
the experiment period, as judged from the body weight 
experiments and pathological changes of the treated and control 
mice during the experiment. Animals were sacrificed for 
histopathological study at different time points. Fig.5 shows the 
representative histopathological changes noted at the application 
sites. It is observed that the inflammatory response (subacute 
response) characterized by increased permeability of capillaries 
and infusion of abundant lymphocytes occurred at the application 
site, which can be subacute host response sets in against the 
foreign material after 7 day of injection. The inflammation is 
increased and there are lots of neutrocytes and lymphocytes on 
day 7. However, new fibroblast cells begin to appear around the 
beam wall of the patch and fibroblast tissue could be observed 
(Fig. 5A). After 14 days, there are a few neutrocytes under the 
dermal layer and superficial layer, but a thick fibrous tissue is 
observed (Figure. 5B). After 21 days, a new and thin fibrous tissue 
is formed under the dermal layer and superficial layer of the 
muscularis and the histology is similar to that of normal skin 
(Figure. 5C). Although there are some signs of high inflammation in 
a few of the tissue samples but usually there is an indication of 
time-related healing process (i.e. time-related acute to subacute 
inflammatory reaction, associate with increased fibroplasia). 
Control group has also shown no inflammation. 
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Figure: 5- Representative histopathological changes noted at the application sites on the 7th(A), 14th (B), 21th (C) (100ï, N, neutrocyte; CF, 
collagenous fiber; FT, fibrous tissues). 
 
Discussion 
Overall results show that Metformin solid lipid nanoparticles 
incorporated in transdermal patch possess marked hypoglycaemic 
activity (when tested in fasted normoglycaemic rats) and 
antihyperglycaemic activity (by lowering the blood glucose levels in 
STZ-induced diabetic rats). Since transdermal delivery of 
Metformin solid lipid nanoparticles showed prominent result 
suggesting that nanoparticle could penetrate through stratum 
corneum, epidermis and dermis to reach the blood circulation. The 
penetration was due to ultrafine particles size of nanoparticles and 
its lipid content [19-21]. The phospholipids vesicles could penetrate 
rapidly when compared to other vesicles [15-16]. This study 
demonstrated the significant quantity of Metformin can be delivered 
into blood stream from a single transdermal nanoparticles patch 
over extended period of time. The ex-vivo permeation studies 
predicted that the high cumulative amount of drug permeated by 
using nanoparticles made by polymethacrylic acid. In-vivo 
experimentation proved that nanoparticles permeation from 
transdermal patch was more at 48 hrs compared to initial hours. It 
was reported that dropping of blood glucoselevel were prolonged 
by transdermal patches upto 48 hrs [22-24]. The slow and 
sustained hypoglycemic response could be due to slow release of 
drug from nanoparticles. In orally treated group, the hypoglycemic 
effect was reduced upto 10 hrs, which could be due to its short 
biological half life. The pharmacokinetic parameters obtained with 
transdermal nanoparticles patches were significantly (p<0.05) 
different from orally treated group. This could be a fast absorption 
and short half life [10]. Whereas nanoparticles through transdermal 
route showed slow release of drug from lipid vesicles and 
maintained peak plasma concentration over a prolonged period 
[24-26]. Transdermal nanoparticulate system would also protect 
the formulation from dehydration and accidental damage, leakage 
of drug from system. Metformin solid lipid nanoparticles 
incorporated in transdermal patch were devoid of unacceptable 
side effects even following chronic administration. On all accounts, 
no significant histological differences are observed between control 
and Transdermal patch applied tissue samples. An acceptable 
tissue reaction to polymeric patch should be temporary 
inflammatory responses. Thus, histopathological studies confirm 
that M-SLN Transdermal patches is biocompatible for use in drug 
delivery systems. There were no overt signs of toxicity and 
hepatotoxicity. In conclusion, our results demonstrate the use of 
Metformin solid lipid Nanoparticle in Transdermal patches for the 
FT
N
BA
c
CF
FT
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first time and show its therapeutic potential to be used as a cost 
effective safe mode of drug delivery systems. 
Conclusion 
We synthesized and characterized Metformin Solid lipid 
nanoparticles which were later incorporated in the transdermal 
patches. Metformin Solid lipid nanoparticles was prepared by the 
Solvent diffusion technique and easily incorporated in transdermal 
patches. Solid lipid nanoparticles system successfully delivered 
Metformin transdermally, as evidenced by a significant sustained 
decrease in blood glucose in normal rat and those with diabetes. 
The biocompatibility and initial inflammation of the M-SLN 
transdermal patches were evaluated from the histopathology of the 
tissue near the application site, which has shown that M-SLN 
transdermal patches have a well biocompatibility. These result 
support the feasibility of developing transdermal metformin for 
human applications. The transdermal delivery of solid lipid 
nanoparticles contained Metformin is safe, economic and 
continuous delivery for diabetes patients. 
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